These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36589665)

  • 1. Molecular profile and clinical features of patients with gliomas using a broad targeted next generation-sequencing panel.
    Romanidou O; Apostolou P; Kouvelakis K; Tsangaras K; Eliades A; Achilleos A; Loizides C; Lemesios C; Ioannides M; Kypri E; Koumbaris G; Papadopoulou K; Papathanasiou A; Rigakos G; Xanthakis I; Fostira F; Kotoula V; Fountzilas G; Patsalis PC
    Oncol Lett; 2023 Jan; 25(1):38. PubMed ID: 36589665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Targeted Next-Generation sequencing Panels for Detection of Somatic Variants in Gliomas.
    Shin H; Sa JK; Bae JS; Koo H; Jin S; Cho HJ; Choi SW; Kyoung JM; Kim JY; Seo YJ; Joung JG; Kim NKD; Son DS; Chung J; Lee T; Kong DS; Choi JW; Seol HJ; Lee JI; Suh YL; Park WY; Nam DH
    Cancer Res Treat; 2020 Jan; 52(1):41-50. PubMed ID: 31096737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
    Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications.
    Tirrò E; Massimino M; Broggi G; Romano C; Minasi S; Gianno F; Antonelli M; Motta G; Certo F; Altieri R; Manzella L; Caltabiano R; Barbagallo GMV; Buttarelli FR; Magro G; Giangaspero F; Vigneri P
    Front Oncol; 2022; 12():861078. PubMed ID: 35372034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Molecular Characterization of Chinese Patients with Glioma by Extensive Next-Generation Sequencing Panel Analysis.
    Zeng C; Wang J; Li M; Wang H; Lou F; Cao S; Lu C
    Cancer Manag Res; 2021; 13():3573-3588. PubMed ID: 33953611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Targeted Next-Generation Sequencing Panel to Genotype Gliomas.
    Guarnaccia M; Guarnaccia L; La Cognata V; Navone SE; Campanella R; Ampollini A; Locatelli M; Miozzo M; Marfia G; Cavallaro S
    Life (Basel); 2022 Jun; 12(7):. PubMed ID: 35888045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic profiling of rat gliomas and cardiac schwannomas from life-time radiofrequency radiation exposure study using a targeted next-generation sequencing gene panel.
    Brooks AM; Vornoli A; Kovi RC; Ton TVT; Xu M; Mashal A; Tibaldi E; Gnudi F; Li JL; Sills RC; Bucher JR; Mandrioli D; Belpoggi F; Pandiri AR
    PLoS One; 2024; 19(1):e0296699. PubMed ID: 38232086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics.
    Synhaeve NE; van den Bent MJ; French PJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Verdijk R; Dirven CMF; Dubbink HJ
    Acta Neuropathol Commun; 2018 Nov; 6(1):126. PubMed ID: 30470264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.
    Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K
    Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Genetic Profile of 300 Japanese Patients with Diffuse Gliomas Using a Glioma-tailored Gene Panel.
    Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Fujio S; Kirishima M; Takigawa K; Hata N; Toh K; Yamamoto J; Hanaya R; Tanimoto A; Yoshimoto K
    Neurol Med Chir (Tokyo); 2022 Sep; 62(9):391-399. PubMed ID: 36031351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases.
    Na K; Kim HS; Shim HS; Chang JH; Kang SG; Kim SH
    J Neurooncol; 2019 May; 142(3):445-454. PubMed ID: 30710203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
    Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
    Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular genetic profiling reveals novel association between FLT3 mutation and survival in glioma.
    Shee K; Chambers M; Hughes EG; Almiron DA; Deharvengt SJ; Green D; Lefferts JA; Andrew AS; Hickey WF; Tsongalis GJ
    J Neurooncol; 2020 Jul; 148(3):473-480. PubMed ID: 32583303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Molecular Genetic Analysis in Glioma Patients by Next Generation Sequencing.
    Kim T; Lee A; Ahn S; Park JS; Jeun SS; Lee YS
    Brain Tumor Res Treat; 2024 Jan; 12(1):23-39. PubMed ID: 38317486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
    Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
    Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens.
    Pallavajjala A; Haley L; Stinnett V; Adams E; Pallavajjala R; Huang J; Morsberger L; Hardy M; Long P; Gocke CD; Eshleman JR; Rodriguez FJ; Zou YS
    Hum Pathol; 2022 Aug; 126():63-76. PubMed ID: 35561840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel.
    Gleeson FC; Voss JS; Kipp BR; Kerr SE; Van Arnam JS; Mills JR; Marcou CA; Schneider AR; Tu ZJ; Henry MR; Levy MJ
    Oncotarget; 2017 Nov; 8(55):93464-93475. PubMed ID: 29212165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
    Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
    Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplicon-Based NGS Panels for Actionable Cancer Target Identification in Follicular Cell-Derived Thyroid Neoplasia.
    Madsen MB; Kiss K; Cilius Nielsen F; Bennedbæk FN; Rossing M
    Front Endocrinol (Lausanne); 2020; 11():146. PubMed ID: 32265839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.